The New Jersey Commission on Science and Technology in 2005 launched the New Jersey Technology Fellowship program providing up to $85,000 for early-stage tech firms in New Jersey hiring selected post doctoral graduates from New Jersey research universities.
“We created the New Jersey Technology fellowships to give early-stage firms what they need most – talented, dedicated employees,” said Commission Chairman Donald L. Drakeman. “We are proud to launch the careers of these young scientists and to help New Jersey entrepreneurs create more quality high-tech jobs in New Jersey.”
3D Biotek, LLC. and Carlos Eduardo Caicedo-Cravajal
PhD Rutgers University, Department of Biochemistry
Using its Precision 3D Microfabrication technology, 3D Biotek is engaged in the development of novel 3-dimensional scaffolds for drug discovery, stem cell research and tissue engineering applications. The tissue engineering product that will be developed at 3D Biotek is a novel porous hybrid scaffold fabricated from a synthetic biodegradable polymer and coated with a bioactive extra cellular matrix (ECM) coating. The primary application of this novel scaffolds will be for the treatment of severely degenerated or damaged bone and cartilage, as tissue degeneration is becoming a severe issue with the ever increasing aged population. This novel product is expected to be a better scaffold than currently available scaffolds for bone/cartilage repair because of the optimized porous structure and ECM coating that closely mimics the living bone/cartilage cell growth environment.
CytoSorbents, Inc. and Humayra Ali
PhD Princeton University, Molecular Biology.
CytoSorbents, Inc is a therapeutic device company that has developed a highly porous polymer bead technology that can remove toxins and other substances from blood to potentially treat many different diseases. The Company is currently in clinical trials in Europe evaluating its flagship product, CytoSorbTM, for the treatment of severe sepsis. Severe sepsis, often called "overwhelming infection", affects all ages, all ethnicities and all walks of life and kills more people in the US each year than either heart attacks, strokes or any single form of cancer. CytoSorbTM has the potential ability to treat the "cytokine storm" in sepsis that is responsible for the organ failure that leads to death in one out of every three patients, despite the best medical treatment. CytoSorbents' patented platform technology is the basis of a number of different resins that have been developed to treat a variety of different diseases.
Lifeblood Medical, Inc and Lisa Canto
PhD UMDNJ, Biochemistry and Molecular Biology.
Lifeblood Medical Inc. has developed a product, LiforCell®, which uses a novel formulation to carry and deliver oxygen to organs, tissues, and cells. LiforCell® has been utilized to increase organ preservation times, and to maintain various highly metabolic cell lines in culture. In the current project, Lifeblood Medical propose to use LiforCell® to maintain the lifespan and drug detoxification and elimination functions of hepatocytes in culture to ultimately be utilized for clinical and pharmaceutical.
New Visual Media Group, LLC, and Judith Sorge
Ph.D. Rutgers University, Material Science and Engineering
The New Visual Media Group dynamic window technology, when installed in residential and commercial windows can substantially increase their energy efficiency, saving the wasted energy cost, equivalent to two million barrels of crude oil daily. This project will advance this dynamic window technology in preparation of its commercialization.This project will further optimize the energy savings properties of the dynamic windows and further reduce their manufacturing cost.
ProFACT Proteomics, Inc., and Amita Oka
Ph.D. Rutgers University; Microbiology
The Company provides Molecular Profiling Services and makes collaborations and alliances. Institutional research projects related to biomarkers are under way at the University of Medicine and Dentistry of New Jersey (UMDNJ) and with investigators at the New Jersey Cancer Institute. A service contract with a major Biopharmaceutical company has recently commenced. Their work will generate research biomarkers for the Microbiologist with benefits similar to those which biomarkers have for medicine. In the case of Biopharma, proteomic biomarkers look into the protein constellation of an organism for an indication of the presence or progression of a disease. For the Microbiologist, a proteomic marker may help identify a particular functioning microorganism among a constellation of microbes.
QRx Pharma, Inc and Marc Carmichael,
Ph.D. UMDNJ, Biomedical Engineering
QRxPharma is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapies for disorders of the central nervous system (CNS). QRxPharma believes that the clinical breakthrough that will underpin the commercial success of its dual opioid drugs is that it combines existing opioids, whose characteristics have been known for many decades, into a lower dosage format that achieves pain relief with fewer side effects and lower associated risks than existing therapies. Most common unmet needs in the market for moderate to severe pain are reduced side effects, improved therapeutic effect, and the availability of different opioid formulations. QRxPharma therefore believes that its drug will offer doctors who prescribe pain drugs a unique clinical option.
Simphotek, Inc., and Kamyar Malakuti,
Ph.D. NJIT Mathematical Sciences.
Simphotek will develop photonics simulation software for biomedical, nanotechnology and photonic materials markets. The software can dramatically reduce the time and cost to study, develop and market new photonic-based products by replacing or augmenting multimillion dollar measurement equipment. The product development cycle can be greatly accelerated if the promising new materials and devices are first designed on CAD software and then tested via computer simulated experiments. Simphotek will license photonics-CAD software to industries, universities and government laboratories that are working to develop new photonic materials and devices.
New Visual Media Group, LLC and Weizhong Chen
Ph.D. NJIT, Applied Physics
New Visual Media Group, LLC is using Electro Polymeric Display (EPD) technology to develop low cost digital billboards and dynamic window shades for energy saving. EPD is an innovative technology using an extremely thin plastic foil which can be rolled or unrolled when voltage is applied.
Signum Biosciences and Jose R. Fernandez
Ph.D. UNDMJ, Cellular and Molecular Pharmacology
Through research on protein networks that control biological systems, Signum Biosciences Inc. is developing therapeutic candidates for Alzheimer's, Parkinson's, diabetes, asthma and several skin conditions. Signum’s STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.
3D Biotek, LLC and Marika Bergenstock
Ph.D. UMDNJ, Biomedical Engineering
3D Biotek LLC intends to commercialize 3D InsertTM – PS, which is a series of novel 3-dimensional (3D) porous scaffolds fabricated from non-cytotoxic and crystal clear polystyrene (PS) for 3D cell/tissue culture applications. The use of 3D InsertTM-PS in stem cell research and drug discovery will provide more realistic physiological results from in vitro cell/tissue culture studies. As a result, the use of 3D InsertTM – PS will decrease the overall therapeutic and pharmaceutical product development cost and shorten the time to market.
Snowdon and Oyenike Olabisi
Ph.D. UMDNJ, Molecular Genetics
Snowdon Inc. is an early-stage pharmaceutical company engaged in the discovery of novel medicines for cancer, neurological disorders, and infectious diseases. Snowdon generates drug candidates with exceptional speed and economy. Starting with high value, well validated biological targets, Snowdon employs its proprietary computational platform technology that rapidly finds initial drug leads from its virtual library of 5+ million commercially available chemicals including FDA-approved drugs. The most attractive drug leads are selected for initial biological evaluation, to ensure that only the most promising candidates proceed to pre-clinical and clinical testing.
Rational Affinity Devices, LLC and Liliana Perez
Ph.D. UMDNJ Physiology and Integrative Biology
Develop novel dyes that light up in the presence of particular cell-types, but not others, and which are minimally perturbing to the continued growth and differentiation of the cell. These gentle dyes will allow the real-time monitoring of cells, including adult stem cells, as they grow and develop, with minimal harm being done to the cells being monitored
AlfaGene Biosciences and David Harrison
Ph.D. UMDNJ, Biochemistry and Molecular Biology.
AlfaGene Bioscience, Inc is currently utilizing a novel technology of primary epithelial cell culture system derived from cancerous and normal tissues from the gastrointestinal (GI) tract and the latest in proteomic research technology to identify bio-molecules involved in colorectal cancer. These biomarkers can be used to diagnose the disease in its early stages of development and can serve as targets for treatment programs as well as to measure effectiveness of therapies.
Niiki Pharma Inc and Rebecca Baerga
Ph.D. UMDNJ, Molecular Biosciences.
Nikki Pharma Inc specializes in identifying and licensing novel anti-cancer drugs and rapidly moving them forward towards commercialization. Niiki Pharma's lead compound, NKP-14, has a novel mechanism of tumor cell killing, which differs from the way other anti-cancer drugs work. www.niikipharma.com
Infostat Inc and Ming-Tsung Ho
Ph.D.Rutgers, Department of Physics and Astronomy
Infostat Inc, DBA K Lab Corporation, will develop and deliver the next generation infrared scene projection system to AF and NAVY for different scene simulation.
Aestus Therapeutics and Meredith Prysak
Ph.D. UMDNJ, Molecular Genetics, Microbiology and Immunology
Aestus is repositioning drug products for development in nervous system diseases of unmet medical need. Dr. Prysak will apply proprietary data mining methods to derive new knowledge of the pathology underlying ALS and other diseases.
Lux Biosciences and Daniel Haders
Ph.D. Rutgers, Biomedical Engineering & Materials Science and Engineering
Lux Biosciences is dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. Dr. Haders will work to develop a treatment for Dry Eye Syndrome.
Neurotez and Steven Greco
Ph.D. UMDNJ, Biomedical Science
Neurotez is in the process of launching the clinical development of a Leptin product as a therapy for Alzheimer's disease. Dr. Greco will expand previous preclinical findings and will explore novel pathways and potentially new targets under the Leptin program. www.neurotez.com
PortaScience and Lizabeth Romero-Perez
PortaScience develops portable and easy-to-use tests for the healthcare, veterinary and consumer markets. Dr. Romero-Perez will be involved in designing new methods to achieve novel data sets. The company hopes to mine these data sets for the commercialization of new biomarkers and potential drug targets.
TRIM-edicine and Christopher Ferrante
Ph.D. UMDNJ, Physiology and Integrative Biology
TRIM-edicine is a biotech company involved in the development of novel pharmaceutical products for treatment of medical conditions related to dermal injury, oral health and wound healing. Dr. Ferrante will test if formulations are effective in a tissue culture wounding model.
Treadstone Technologies and Joshua Finch
Ph.D. Rutgers, Material Science Engineering
Treadstone is dedicated to the commercialization of alternative energy technologies that support and enable the use of alternative energy sources for portable, stationary and transportation application. The fellow will work on the metal plate and hydrogen technology development program.
Advaxis Inc and Kyla Driscoll-Carroll
Ph.D. UMDNJ, Microbiology and Molecular Genetics
Advaxis Inc is focused on identifying candidate vaccine antigens expressed by cells in cancers associated with EBV and KSHV. The goal is to investigate the feasibility and potential efficacy of developing new cancer vaccines.
ExSAR Corp and Deepangi Pandit
Ph.D. NJIT, Chemistry
ExSAR is a biopharmaceutical company utilizing a hydrogen/deuterium exchange mass spectrometry technology platform in support of in-house drug discovery efforts and fee-for-service projects on drug discovery to pharmaceutical companies and academic laboratories. Dr. Pandit will aid in the interpretation of the data and design of better drugs.
Phytomedics and Caren Villano
Ph.D. Rutgers University, Toxicology
Phytomedics uses an innovative proprietary technology platform to discover, develop, manufacture and commercialize novel, multi-component and multi-functional botanical therapeutics. Dr. Villano will develop and implement unique screening technologies, which are compatible with botanical extracts for the discovery and the development of the company’s products.
Storage Engine and Karen Hare
Ph.D. NJIT, Information Systems
Storage Engine is aware of the needs of hospitals in NJ as well as other states to solve critical data storage, access and control issues to meet the needs of their community. Dr. Hare will enhance current services by providing current technology to assist doctors, caregivers & patients access to information.
UV Solutions and Jenny Mahoney
Ph.D. Stevens Institute of Technology, Physics and Engineering Physics
UV Solutions is engaged in the development of an innovative and efficient method for the production of ultraviolet light. Dr. Mahoney will optimize the carbon nanotube electron beam pumped excimer lamps currently under development at the company.
Pradeep Bhatta and Princeton Satellite Systems
Ph.D Princeton University, Mechanical and Aerospace Engineering
Princeton Satellite Systems specializes in innovative, cost effective solutions to control system design problems. Dr. Bhatta is working at Princeton Satellite Systems on control methods for various mechanical and aerospace engineering applications. His projects include improving wind power extraction efficiency and improvements to autonomous underwater vehicles. www.psatellite.com
Kelly Corcoran and Chromocell Corporation
Ph.D. UMDNJ, Biology
Chromocell enables crafting of cell lines and cell based assays that were out of reach until today. Dr. Corcoran is working at Chromocell Corporation using their patented Chromovert technology to sort out stem cells for use in future clinical applications.
Eiman Elnahrawy and Kordinate, LLC
Ph.D. Rutgers University, Computer Science
Kordinate L.L.C. provides positioning and tracking software for any device with a packet radio. Dr. Elnahrawy is developing cost-effective localization and tracking products for the industrial, scientific, medical and consumer markets.
Ankur Gandhi and Orthocon, Inc.
Ph.D. NJIT, Biomedical Engineering
Orthocon is focused on the development of new and innovative products for the orthopaedic and spine surgery markets. Dr. Gandhi is overseeing in vitro and in vivo pre-clinical testing to assess safety and efficacy of devices to deliver analgesic. The devices offer the opportunity to manage pain associated with orthopaedic procedures.
Eduardo Perez and Signum Biosciences
Ph.D. UMDNJ & Rutgers University, Biochemistry & Molecular Biology
Signum Biosciences is applying the tools of molecular biochemistry to design and identify compounds to prevent and treat diseases. Dr. Perez is working at Signum Biosciences to characterize compounds that may be used as new anti-inflammatory agents that will compete with or supplement those currently in use.
Meghan Tierney and ProFACT Proteomics
Ph.D. Rutgers University, Environmental Science
ProFACT Proteomics is utilizing new technologies for the systemic study of proteins and diseases. Dr. Tierney is working at ProFACT Proteomics to develop protocols for ProFACT’s patented SeraFILETM system with the optimum goal of using this technology to identify differences in diseased and non-diseased protein samples.
Andrew Colasanti and Provid Pharmaceuticals
PhD Rutgers University, Department of Molecular Biology
Provid Pharmaceuticals Inc., 732 980-9229
Piscataway; 15 employees
Provid Pharmaceuticals is a chemistry-based drug discovery company with proprietary technology and successful internal research. Provid builds relationships with biotech companies and academic groups that have outstanding biology, but need high-level chemistry expertise to invent the drug compounds that are the currency of the pharmaceutical industry. Dr. Colasanti is expected to develop new tools for drug discovery to enhance the company’s research programs.
David Fela and Signum Biosciences
Ph.D. Rutgers University, Biochemistry
Signum Biosciences, Inc. 732 329-6344
South Brunswick, 6 employees
Signum Biosciences is applying the tools of molecular biochemistry to design and identify compounds to prevent and treat diseases originating from a failure within the signaling system of human cells, including Alzheimer’s Parkinson’s and various skin conditions. Dr. Fela is expected to develop botanical extracts that can be used to treat neurological diseases.
Gregory Kornhaber and ExSAR Corporation
PhD University of Medicine and Dentistry of New Jersey and Rutgers University, Molecular Biosciences
ExSAR Corporation, 732 438-6500
South Brunswick; 5 employees
In addition to conducting proprietary research in the development of automated methods for the analysis of protein structures, ExSAR sells access to its proprietary technology through research service contracts. ExSAR’s customers include large and mid-sized pharmaceutical companies, biotechnology companies, and academic researchers. ExSAR has contracts with Aventis, Bristol Myers-Squibb, Johnson&Johnson, Merck and GlaxoSmithKline. Dr. Kornhaber is expected to help move the company from contract research to developing their own drug targets.
James Nehlsen and Exelus Incorporated
Ph.D. Princeton University, Chemical Engineering
Exelus Inc. 973 740-2350
Livingston, 5 employees
The company’s mission is to create cleaner-by-design process technologies to meet the dual challenges of improving fuel efficiency and developing environmentally friendly processes to make fuels. Exelus’ vision is to lower costs for hydrogen production by simplifying reactor design and completely eliminating need for hydrogen purification by using innovative chemistry. Dr. Nehlsen’s work has concentrated on removing sulfur from petroleum. Dr. Nehlsen is expected to develop a new device to improve Exelus hydrogen technology and other fuel processes.
Anamika Patel and Energy Photovoltaics, Inc.
Ph.D. New Jersey Institute of Technology, Electrical Engineering
Energy Photovoltaics, Inc. 609 587-3000
Lawrenceville, 53 employees
Energy Photovoltaics, Inc. has focused on development of thin film photovoltaic modules to provide economical solar electricity. Dr. Patel is expected to help increase the power output of its modules, making the company’s product more competitive in the marketplace.
James Flint and PharmaSeq
PhD. Rutgers University, Biomedical Engineering
PharmaSeq 732 355-0100 x11
Wlodek Mandecki, president
PharmaSeq provides ultra high-throughput, low-cost multiplex bioassays and instruments for research and clinical use. The company pioneered a unique technology based on an ultra-small silicon integrated circuit, a microtransponder, which when activated by laser light emits a radio frequency signal carrying a unique identification code. Applications are being pursued in genomics, proteomics, pharmaceutical drug discovery and combinatorial chemistry. www.pharmaseq.com
Kathleen Gilbert and Pestka Biomedical Laboratories
PhD New Jersey Institute of Technology, Chemistry and Environmental Science.
Pestka Biomedical Laboratories 732 777-9123 x 20
Director of Drug Development and Discovery William Clark, PhD.
Pestka Biomedical Laboratories focuses on treating patients with better targeted, more effective therapeutic molecules and/or routes of administration in order to minimize adverse side effects. The company’s founder, Dr. Sidney Pestka, was awarded the 2001 National Medal of Technology for his focus on innovation biotechnology and the dramatic impact his effort have had on the treatment of diseases including hepatitis C, multiple sclerosis and cancer. Dr. Clark is collaborating with UMDNJ researchers to develop novel treatments for infections diseases and cancer.
Nazieh Masoud and UV Solutions
Ph.D. Stevens Institute of Technology, Physics and Engineering Physics
UV Solutions 973 242-8900
Janet George Murnick, PhD. Interim president
UV Solutions, at the Enterprise Development Center technology incubator on the NJIT campus, is focusing on ozone treatment of water and wastewater, which is preferred by the EPA and the DEP as a safer method than disinfecting by mercury lamps and which leaves no toxic residue as in chlorination.